TEAMLAB
8.8.2019 12:48:06 CEST | Business Wire | Press release
This summer marks the one-year anniversaries for art collective teamLab’s two museums in Tokyo: MORI Building DIGITAL ART MUSEUM: teamLab Borderless (Odaiba, Tokyo; hereafter teamLab Borderless) and teamLab Planets TOKYO (Toyosu, Tokyo; hereafter teamLab Planets). In the one year since their openings, teamLab Borderless and teamLab Planets have seen a combined 3.5 million visitors. teamLab Borderless alone welcomed 2.3 million visitors within one year of opening, exceeding the number of attendees at the Van Gogh Museum in the Netherlands and setting a record number of visitors at a single-artist museum in one year. These visitors came from over 160 countries and regions around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190808005373/en/
teamLab Borderless and teamLab Planets are two museums dedicated solely to art by teamLab. teamLab Borderless is a world of ever-changing artworks without boundaries, a “museum without a map.” One year since its opening in June, 2018, the museum has seen approximately 2.3 million visitors from over 160 countries and regions worldwide. teamLab Planets is “a museum where you move through water.” Guests walk barefoot in the space and physically immerse their entire bodies in massive artworks. One year since its opening in July, 2018, the museum has welcomed over 1.25 million visitors from 106 countries and regions around the world.
When compared to the world’s three most-visited single-artist museums of 2018, both teamLab Borderless and teamLab Planets welcomed more visitors than the Picasso Museum in Barcelona, Spain (948,483 visitors), and the Dalí Theatre-Museum in Figueres, Spain (1,105,169 visitors). The number of museum attendees at teamLab Borderless exceeds even those of the Van Gogh Museum in Amsterdam, Netherlands (2,161,160 visitors), making it the world’s most-visited museum dedicated to a single artist. (*1).
- teamLab Borderless (Odaiba, Tokyo)
Of the 2.3 million visitors to teamLab Borderless, approximately 50% come from overseas (*2), with most coming from the USA, followed by Australia, China, Thailand, Canada, and the UK, making it a museum that attracts not only visitors from neighboring countries, but those from far more distant regions as well. In addition, according to a survey conducted by the museum, it appears that about 50% of the guests from overseas visited Tokyo in order to visit the museum (*3).
- teamLab Planets (Toyosu, Tokyo)
Of the 1.25 million visitors to teamLab Planets, approximately 30% come from overseas (*4), with the majority coming from the USA, followed by Hong Kong, Taiwan, the UK, and Australia.
-----------------------
*1 ”THE ART NEWSPAPER SPECIAL REPORT Art’s Most Popular: Exhibition and museum visitor figures 2018” The Art Newspaper. Number 311, April, 2019.
*2 teamLab Borderless Official Website, Ticket Purchasing Data (data obtained Feb 16 - June 7, 2019)
*3 teamLab Borderless Visitor Survey (conducted Oct 25 - Nov 2, 2018), 1,237 respondents
*4 teamLab Planets Official Website, Ticket Purchasing Data (data obtained March 1 - June 30, 2019)
About teamLab
teamLab (f. 2001) is an art collective, interdisciplinary group of ultratechnologists whose collaborative practice seeks to navigate the confluence of art, science, technology, design and the natural world. teamLab aims to explore a new relationship between humans and nature, and between oneself and the world through art. Click here
for full bio.
teamLab is represented by Pace Gallery
.
Press Kit
teamLab Borderless
https://goo.gl/MpzVss
For tickets and more information, please visit borderless.teamlab.art
, and follow Instagram
.
teamLab Planets
https://goo.gl/tQXMLm
For tickets and more information, please visit planets.teamlab.art
, and follow Instagram
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190808005373/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom